OC METRO CALENDAR

  • March 2010
    SuMoTuWeThFrSa
    28123456
    78910111213
    14151617181920
    21222324252627
    28293031123
    45678910
Add an event

PHARMACEUTICALS
Untitled Page

Spectrum Pharmaceuticals moves forward with bladder cancer drug

Irvine firm is working with Nippon Kayaku to develop apaziquone in Asia.

By Kristen SchottPublished: November 10, 2009 09:47 AM

  • Print This Article
  • Email This Article
  • Share/Bookmark
  • Irvine-based Spectrum Pharmaceuticals is collaborating with Nippon Kayaku, a Tokyo-based general chemical firm, to develop and commercialize Spectrum's nonmuscle invasive bladder cancer therapy, apaziquone, in Asian territories.

    The total value of the agreement is more than $151 million, and Spectrum will receive $15 million from Nippon Kayaku upfront. Nippon will make additional payments of up to $136 million if certain regulatory and commercial achievements are met.

    This is the second collaboration the commercial-stage biotech firm has entered into for the drug. Spectrum is also working with Irvine-based Allergan to market apaziquone in North America and Europe, among other areas. The partnerships help to support Spectrum's goal to develop the treatment worldwide.

    “Nippon Kayaku is one of the most established and reputable pharmaceutical companies in Japan and has unparalleled experience in Asia in the field of nonmuscle invasive bladder cancer and prostate cancer," says Rajesh C. Shrotriya, M.D., chairman, CEO and president of Spectrum.

    NEXT PAGE >>


    Related headlines
    UC Irvine sees success with embryonic stem cell therapy
    Aliso Viejo's OCTANe gears up for medical device forum
    Irvine's BlueFire gets $3.8 million for biorefinery